Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models

Journal of Molecular and Cellular Cardiology

Volumn 65, Issue , 2013, Pages 1-8

  Gu, Jun ^a   Liu, Xu ^a   Wang, Quan xing ^b   Guo, Meng ^b   Liu, Fang ^b   Song, Zhi ping ^a   Zhang, Da dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Atrial electrical remodeling; Atrial structural remodeling; PPAR agonists; Signaling pathway

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CALCIUM CHANNEL L TYPE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; ARTICLE; ATRIAL ELECTRICAL REMODELING; ATRIAL REMODELING; ATRIAL STRUCTURAL REMODELING; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ELECTRIC CURRENT; FIBROBLAST CULTURE; HEART ATRIUM; HEART DISEASE; HEART MUSCLE CELL; HL 1 CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ATRIAL ELECTRICAL REMODELING; ATRIAL STRUCTURAL REMODELING; PPAR-Γ AGONISTS; SIGNALING PATHWAY;

ANGIOTENSIN II; ANIMALS; ATRIAL REMODELING; CARDIOTONIC AGENTS; CELL PROLIFERATION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; ELECTROPHYSIOLOGICAL PHENOMENA; FIBROBLASTS; HEART ATRIA; ION CHANNEL GATING; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; PHOSPHORYLATION; PHOSPHOSERINE; PPAR GAMMA; PROTEIN SUBUNITS; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; SMAD PROTEINS; THIAZOLIDINEDIONES; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84885569542     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.09.016     Document Type: Article

References (43)

1. Iwasaki Y.K., Nishida K., Kato T., Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation 2011, 124:2264-2274.
2. Tsai C.T., Wang D.L., Chen W.P., Hwang J.J., Hsieh C.S., Hsu K.L., et al. Angiotensin II increases expression of alpha1C subunit of L-type calcium channel through a reactive oxygen species and cAMP response element-binding protein-dependent pathway in HL-1 myocytes. Circ Res 2007, 100:1476-1485.
3. Tsai C.T., Chiang F.T., Chen W.P., Hwang J.J., Hsieh C.S., Hsu K.L., et al. Angiotensin II induces complex fractionated electrogram in a cultured atrial myocyte monolayer mediated by calcium and sodium-calcium exchanger. Cell Calcium 2011, 49:1-11.
4. Adam O., Lavall D., Theobald K., Hohl M., Grube M., Ameling S., et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol 2010, 55:469-480.
5. Tsai C.T., Lai L.P., Hwang J.J., Chen W.P., Chiang F.T., Hsu K.L., et al. Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation. J Hypertens 2008, 26(3):570-582.
6. Hao G.H., Niu X.L., Gao D.F., Wei J., Wang N.P. Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol 2008, 153:1409-1419.
7. Zhao S.M., Shen L.H., Li H.W., Wang L., Chen H., Wang Y.L., et al. Down-regulation of the expression of angiotensin II type 1 receptor in neonatal rat cardiac fibroblast by activation of PPARgamma signal pathway. Chin J Physiol 2008, 51:357-362.
8. Marchesi C., Rehman A., Rautureau Y., Kasal D.A., Briet M., Leibowitz A., et al. Protective role of vascular smooth muscle cell PPARgamma in angiotensin II-induced vascular disease. Cardiovasc Res 2013, 97:562-570.
9. Han C.J., Liu J.T., Li M., Cui M., Pang X.M., Mao J.J., et al. Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway. Inflamm Res 2012, 61:1031-1037.
10. Xu D., Murakoshi N., Igarashi M., Hirayama A., Ito Y., Seo Y., et al. PPAR-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. J Cardiovasc Electrophysiol 2012, 23:209-217.
11. Shimano M., Tsuji Y., Inden Y., Kitamura K., Uchikawa T., Harata S., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008, 5:451-459.
12. Gu J., Liu X., Wang Q.X., Tan H.W., Guo M., Jiang W.F., et al. Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts. Exp Cell Res 2012, 318:2105-2115.
13. Xiao H.D., Fuchs S., Campbell D.J., Lewis W., Dudley S.C., Kasi V.S., et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004, 165:1019-1032.
14. He X., Gao X., Peng L., Wang S., Zhu Y., Ma H., et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ Res 2011, 108:164-175.
15. Bosch R.F., Zeng X., Grammer J.B., Popovic K., Mewis C., Kühlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999, 44:121-131.
16. Khatib R., Joseph P., Briel M., Yusuf S., Healey J. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol 2012, 165:17-24.
17. Chilukoti R.K., Mostertz J., Bukowska A., Aderkast C., Felix S.B., Busch M., et al. Effects of irbesartan on gene expression revealed by transcriptome analysis of left atrial tissue in a porcine model of acute rapid pacing in vivo. Int J Cardiol 2013, 168:2100-2108.
18. Lu Y.Y., Chen Y.C., Kao Y.H., Wu T.J., Chen S.A., Chen Y.J. Extracellular matrix of collagen modulates intracellular calcium handling and electrophysiological characteristics of HL-1 cardiomyocytes with activation of angiotensin II type 1 receptor. J Card Fail 2011, 17:82-90.
19. Wakili R., Voigt N., Kääb S., Dobrev D., Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 2011, 121:2955-2968.
20. 2+ signaling during atrial fibrillation. J Mol Cell Cardiol 2013, 58:134-142.
21. Yeh Y.H., Wakili R., Qi X.Y., Chartier D., Boknik P., Kääb S., et al. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 2008, 1:93-102.
22. Tsai C.T., Tseng C.D., Hwang J.J., Wu C.K., Yu C.C., Wang Y.C., et al. Tachycardia of atrial myocytes induces collagen expression in atrial fibroblasts through transforming growth factor β1. Cardiovasc Res 2011, 89:805-815.
23. On Y.K., Jeon E.S., Lee S.Y., Shin D.H., Choi J.O., Sung J., et al. Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. J Thorac Cardiovasc Surg 2009, 137:1515-1520.
24. Verheule S., Sato T., Everett T., Engle S.K., Otten D., Rubart-von der Lohe M., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004, 94:1458-1465.
25. Kiryu M., Niwano S., Niwano H., Kishihara J., Aoyama Y., Fukaya H., et al. Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model. Europace 2012, 14:1206-1214.
26. Panek A.N., Posch M.G., Alenina N., Ghadge S.K., Erdmann B., Popova E., et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS ONE 2009, 4:e6743.
27. Abreu J.G., Ketpura N.I., Reversade B., De Robertis E.M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002, 4:599-604.
28. Vermes E., Tardif J.C., Bourassa M.G., Racine N., Levesque S., White M., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003, 107:2926-2931.
29. Hung C.Y., Lin C.H., Wang K.Y., Huang J.L., Hsieh Y.C., Loh E.W., et al. Dosage of statin, cardiovascular comorbidities, and risk of atrial fibrillation: a nationwide population-based cohort study. Int J Cardiol 2013, 168:1131-1136.
30. Nodari S., Triggiani M., Campia U., Manerba A., Milesi G., Cesana B.M., et al. n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation 2011, 124:1100-1106.
31. Gu J., Liu X., Wang X., Shi H., Tan H., Zhou L., et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011, 13:1256-1261.
32. Chao T.F., Leu H.B., Huang C.C., Chen J.W., Chan W.L., Lin S.J., et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol 2012, 156:199-202.
33. Subramanian V., Golledge J., Ijaz T., Bruemmer D., Daugherty A. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell specific interaction with PPAR{gamma}. Circ Res 2010, 107:953-958.
34. Saiki A., Ohira M., Endo K., Koide N., Oyama T., Murano T., et al. Pioglitazone decreases plasma angiotensin II concentration in type II diabetes. J Atheroscler Thromb 2010, 17:651-657.
35. Kume O., Takahashi N., Wakisaka O., Nagano-Torigoe Y., Teshima Y., Nakagawa M., et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011, 8:278-285.
36. Hou X., Zhang Y., Shen Y.H., Liu T., Song S., Cui L., et al. PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1. Eur J Pharmacol 2013, 715:196-203.
37. Lee S.J., Yang E.K., Kim S.G. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Mol Pharmacol 2006, 70:415-425.
38. Han S., Ritzenthaler J.D., Rivera H.N., Roman J. Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1. Am J Physiol Lung Cell Mol Physiol 2005, 289:L419-L428.
39. Scoditti E., Massaro M., Carluccio M.A., Distante A., Storelli C., De Caterina R. PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium. Cardiovasc Res 2010, 86:302-310.
40. Imayama I., Ichiki T., Inanaga K., Ohtsubo H., Fukuyama K., Ono H., et al. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 2006, 72:184-190.
41. Desouza C.V., Gerety M., Hamel F.G. Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells. Vascul Pharmacol 2009, 51:162-168.
42. Pan H.W., Xu J.T., Chen J.S. Pioglitazone inhibits TGFbeta induced keratocyte transformation to myofibroblast and extracellular matrix production. Mol Biol Rep 2011, 38:4501-4508.
43. Mao R., Fan Y., Mou Y., Zhang H., Fu S., Yang J. TAK1 lysine 158 is required for TGF-beta-induced TRAF6-mediated Smad-independent IKK/NF-kappaB and JNK/AP-1 activation. Cell Signal 2011, 23:222-227.